Ketanserin Antibody (101): sc-66079

Ketanserin Antibody (101) is a mouse monoclonal IgG1 antibody that detects Ketanserin protein of non-species reactive by western blotting (WB). Anti-Ketanserin antibody (101) is available as a non-conjugated format. Ketanserin is a selective serotonin receptor antagonist primarily known for its high affinity for the serotonin 5-HT2A receptor, while also exhibiting weaker interactions with the 5-HT2C, 5-HT2B, 5-HT1D, α-adrenergic, and dopamine receptors. Ketanserin plays a crucial role in modulating various physiological processes, including vasodilation and neurotransmission, which are essential for maintaining cardiovascular health and regulating mood. Ketanserin′s ability to improve renal function by significantly increasing creatinine clearance and urine output highlights therapeutic potential, particularly in managing essential hypertension and inhibiting platelet aggregation, especially in older patients. Ketanserin may serve as a promising non-dopaminergic target for therapies aimed at treating basal ganglia disorders such as Parkinson′s disease. With a molecular weight of 395.43 g/mol, Ketanserin is valuable as a radioligand in receptor binding assays when labeled with tritium, further underscoring versatility in both research and clinical applications.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Ketanserin Antibody (101) References:

1. [3H]-ketanserin binding sites in different psychiatric disorders.  |  Marazziti, D., et al. 2003. Neurochem Int. 42: 511-6. PMID: 12547650
2. Effects of low-dose ketanserin on blood pressure variability, baroreflex sensitivity and end-organ damage in spontaneously hypertensive rats.  |  Xie, HH., et al. 2005. Clin Sci (Lond). 108: 547-52. PMID: 15707387
3. Modulation of hematopoiesis by ketanserin in erythropoietin-treated uremic patients: evidence from platelet studies.  |  Borawski, J., et al. 1998. Platelets. 9: 31-5. PMID: 16793742
4. Effect of ketanserin and amphetamine on nigrostriatal neurotransmission and reactive oxygen species in Parkinsonian rats. In vivo microdialysis study.  |  Nowak, P., et al. 2006. J Physiol Pharmacol. 57: 583-97. PMID: 17229983
5. Antihypertensive therapy with ketanserin: effects on central and renal hemodynamics, and microalbuminuria.  |  Casagrande, P., et al. 1990. Int J Clin Pharmacol Ther Toxicol. 28: 79-83. PMID: 2307549
6. Alpha-adrenergic blockade makes minimal contribution to ketanserin's hypotensive effect.  |  Naslund, TC., et al. 1988. Clin Pharmacol Ther. 44: 699-703. PMID: 2904312
7. The influence of ketanserin or urapidil on haemodynamics, stress response and kidney function during operations for myocardial revascularisation.  |  Petry, A., et al. 1995. Anaesthesia. 50: 312-6. PMID: 7747847
8. Beneficial influence of ketanserin on autoregulation of blood flow in post-ischemic kidneys.  |  Verbeke, M., et al. 1996. J Am Soc Nephrol. 7: 621-7. PMID: 8724897
9. Role of ketanserin in the treatment of the essential arterial hypertension associated with ischemic heart disease.  |  Podoleanu, D. and Cotoi, S. 1996. Rom J Intern Med. 34: 49-54. PMID: 8908630